DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 8,317.974 B2 Duggirala Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 8,317.974 B2 Duggirala Et Al US008317974B2 (12) United States Patent (10) Patent No.: US 8,317.974 B2 Duggirala et al. (45) Date of Patent: *Nov. 27, 2012 (54) DEINKING ACELLULOSIC SUBSTRATE (51) Int. Cl. USING MAGNESUM HYDROXDE D2C5/02 (2006.01) 52) U.S. Cl. ..................................... 162/8: 162/4; 162/5 (75) Inventors: Prasad Y. Duggirala, Naperville, IL (52) O A O s s (US); Michael J. Murcia, DeKalb, IL (58) Field of Classification Search ................... 162/4-8 (US s s See application file for complete search history. (73) Assignee: Nalco Company, Naperville, IL (US) (56) References Cited (*) Notice: Subject to any disclaimer, the term of this U.S. PATENT DOCUMENTS past list: G adjusted under 35 8,133,351 B2* 3/2012 Duggirala et al. ................ 162/8 M YW- y yS. * cited by examiner This patent is Subject to a terminal dis claimer. Primary Examiner — Anthony Calandra (21) Appl. No.: 13/366,644 (74) Attorney, Agent, or Firm — Califee, Halter & Griswold LLP (22) Filed: Feb. 6, 2012 (65) Prior Publication Data (57) ABSTRACT US 2012/O135908A1 May 31, 2012 A composition and method for deinking is disclosed. The composition and method contain an activated magnesium Related U.S. Application Data hydroxide or a magnesium hydroxide. (63) Continuation of application No. 12/169,900, filed on Jul. 9, 2008, now Pat. No. 8,133,351. 3 Claims, 2 Drawing Sheets Witeness 78 FS f4 F. 38 8383-2 $g 38-33 3: d Siksia: 3-3E OA afi: higi 3-3 U.S. Patent Nov. 27, 2012 Sheet 1 of 2 US 8,317.974 B2 is 3. 2.340 8. 88: 1586 49. 493 is 24 it 3: i FIG RE SO Brightness 4.32 SR -- -: FCGRE 2 U.S. Patent Nov. 27, 2012 Sheet 2 of 2 US 8,317.974 B2 23.4.8.878S. $43-33 as gf8: FGRE 3 Whiteness 8 :hic38. kg 3-32 Ag3-3 aid is: S&c. 8-2 s FIGRE US 8,317,974 B2 1. 2 DENKINGA CELLULOSC SUBSTRATE The present invention further provides for a method of USING MAGNESUM HYDROXDE removing ink from a cellulosic containing Substance com prising: (a) adding to the Substance a composition compris This application is a continuation application of U.S. ing: (1) magnesium hydroxide, (2) a Suspending agent for patent application Ser. No. 12/169,900, filed Jul.9, 2008, now said magnesium hydroxide, (3) water, and (4) optionally an U.S. Pat. No. 8,133,351. emulsifier; (b) optionally excluding adding caustic soda to the cellulosic containing Substance; and (c) optionally excluding FIELD OF THE INVENTION adding hydrogen peroxide to the cellulosic containing Sub Stance. The invention pertains to compositions and methods for 10 deinking a cellulosic Substrate. BRIEF DESCRIPTION OF THE DRAWINGS BACKGROUND OF THE INVENTION FIG. 1 shows residual ink data after the application of an activated magnesium hydroxide and emulsified TOFA for Efficiently removing ink from secondary fiber without 15 mulation to fiber. impacting fiber quality is one of the major challenges in paper FIG. 2 shows ISO brightness after the application of an recycling. Currently, the most widespread method of remov activated magnesium hydroxide and emulsified TOFA for ing ink from secondary fiber is an alkaline process that uses mulation to fiber. Sodium hydroxide, Sodium silicate, hydrogen peroxide, Sur FIG. 3 shows sheet yellowness after the application of an factants and chelants. The caustic is used to elevate the pH in activated magnesium hydroxide and emulsified TOFA for the repulper causing the fiber to Swell, which assists in ink mulation to fiber. detachment, but also yellows the fiber due to interaction with FIG. 4 shows fiber whiteness after the application of an lignin in mechanical grades, resulting in a brightness loss. activated magnesium hydroxide and emulsified TOFA for Peroxide is added to reduce fiber yellowing, and chelant is mulation to fiber. added to prevent peroxide degradation by metals. Surfactants 25 are used to manage the detached ink and prevent redeposition DETAILED DESCRIPTION OF THE INVENTION onto the fiber. While the conventional method of deinking is effective for A. Definitions ink removal, it has disadvantages. When the cost of the chemicals needed to overcome the unwanted effects of caus 30 "Suspending agent’ means one or more agents that pre tic is considered, the alkaline method is quite expensive. vents precipitation of a stabilized dispersion of colloidal par Aside from the high cost of the chemicals used, handling ticles in solution. caustic can be hazardous, and it is critical to maintain the 'Activated magnesium hydroxide' means a formulation proper balance of caustic, peroxide and silicate to produce that includes magnesium hydroxide plus one or more com fiber with the desired optical properties. Moreover, any ponents that provides additional deinking performance over residual fiber yellowing, or chromophoric generation, that is 35 the magnesium hydroxide alone, e.g. oil added as formulation caused by caustic and cannot be removed with bleaching is with magnesium hydroxide. For example, if the magnesium balanced blue dye to the fiber. While this is effective for hydroxide is mixed with an oil and that oil meets the require achieving a neutral color balance, it reduces ISO brightness, ments of providing additional deinking performance, then the making it difficult to reach brightness targets. In addition, a magnesium hydroxide is an activated magnesium hydroxide. recent study showed that fiber strength and tensile index was 40 “Recycling process' means any process that involves the reduced for secondary fiber deinked under alkaline condi handling of secondary fibers. tions. Finally, the elevated pH in the pulper saponifies adhe “TOFA' means tall oil fatty acid. sives, thereby introducing more Stickies into the papermaking “%' means percent by weight of the composition. system, which cause runnability problems for the paper machine. 45 B. Compositions An improved methodology is therefore desired. As stated above, the present invention provides for a com SUMMARY OF THE INVENTION position comprising: (a) activated magnesium hydroxide; (b) optionally a Suspending agent for said activated magnesium The present invention provides for a composition compris 50 hydroxide; (c) water; (d) optionally an emulsifier; (e) option ing: (a) activated magnesium hydroxide; (b) optionally a sus ally excluding adding caustic Soda; and (f) optionally exclud pending agent for said activated magnesium hydroxide; (c) ing hydrogen peroxide. The present invention also provides water; (d) optionally an emulsifier; (e) optionally excluding for a composition comprising: (a) magnesium hydroxide; (b) caustic soda, and (f) optionally excluding hydrogen peroxide. a suspending agent for said magnesium hydroxide; (c) water; The present invention also provides for a composition (d) optionally an emulsifier; (e) optionally excluding caustic comprising: (a) magnesium hydroxide; (b) a Suspending 55 Soda; and (f) optionally excluding hydrogen peroxide. agent for said magnesium hydroxide; (c) water; (d) optionally In one embodiment, the Suspending agent is a thickening an emulsifier; (e) optionally excluding caustic Soda; and (f) agent. optionally excluding hydrogen peroxide. In another embodiment, the thickening agent is selected The present invention also provides for a method of remov from the group consisting of galactomannans, guar gum, ing ink from a cellulosic containing Substance comprising: (a) 60 locust bean gum, Xanthan gum, para gum, cellulosics; adding to the Substance a composition comprising: (1) acti hydroxypropyl methylcellulose; hydroxypropyl cellulose; vated magnesium hydroxide, (2) water, (3) optionally a sus carrageean; alginates; Sodium alginates; potassium alginates, pending agent for said activated magnesium hydroxide, and ammonium salt alginates; and a combination thereof. (4) optionally an emulsifier; (b) optionally excluding adding In another embodiment, the composition contains from caustic soda to the cellulosic containing Substance; and (c) 65 about 5% to about 70% of said activated magnesium hydrox optionally excluding adding hydrogen peroxide to the cellu ide/magnesium hydroxide, based upon weight of the compo losic containing Substance. sition. US 8,317,974 B2 3 4 In another embodiment, the composition contains about from the resulting deinked fiber. In addition to optical prop 47% of said activated magnesium hydroxide/magnesium erties, an ink speck count measurement is used to evaluate the hydroxide, based upon weight of the composition. efficiency with which the ink is removed. Residual ink can be In another embodiment, the composition contains from expressed in terms of speckS/unit area, percent coverage of about 0.05% to about 20% of said suspending agent, based ink specks on an area, or effective residual ink concentration upon weight of the composition. (ERIC), which is commonly expressed in ppm. In another embodiment, the composition contains about In one embodiment, the cellulosic Substance is located 0.4% of said Suspending agent, based upon weight of the anywhere in a recycling process up through one or more composition. flotation accepts. In another embodiment, the composition comprises an oil. 10 In another embodiment, the emulsifier is added separately In another embodiment, the composition contains from to the cellulosic containing Substance. about 2% to about 55% of said oil based upon the weight of In another embodiment, the Suspending agent is a thicken the composition. ing agent. In another embodiment, the composition contains about In another embodiment, the thickening agent is selected 30% of said oil based upon the weight of the composition. 15 from the group consisting of galactomannans, guar gum, In another embodiment, the oil contains a fatty acid. locust bean gum, Xanthan gum, para gum, cellulosics; In another embodiment, the oil is used to form an oil and water emulsion. hydroxypropyl methylcellulose; hydroxypropyl cellulose; In another embodiment, the composition contains from carrageean; alginates; Sodium alginates; potassium alginates, about 0.5% to about 20% of said emulsifier. ammonium salt alginates; and a combination thereof. In another embodiment, the composition contains about In another embodiment, the composition contains from 3% of said emulsifier.
Load more

Recommended publications
  • Chemicals Used for Chemical Manufacturing Page 1 of 2
    Chemicals used for Chemical Manufacturing Page 1 of 2 Acetic Acid (Glacial, 56%) Glycol Ether PMA Acetone Glycol Ether PNB Acrylic Acid Glycol Ether PNP Activated Carbon Glycol Ether TPM Adipic Acid Glycols Aloe Vera Grease Aluminum Stearate Gum Arabic Aluminum Sulfate Heat Transfer Fluids Amino Acid Heptane Ammonium Acetate Hexane Ammonium Bicarbonate Hydrazine Hydrate Ammonium Bifluoride Hydrochloric Acid (Muriatic) Ammonium Chloride Hydrogen Peroxide Ammonium Citrate Hydroquinone Ammonium Hydroxide Hydroxylamine Sulfate Ammonium Laureth Sulfate Ice Melter Ammonium Lauryl Sulfate Imidazole Ammonium Nitrate Isobutyl Acetate Ammonium Persulfate Isobutyl Alcohol Ammonium Silicofluoride Calcium Stearate Dipropylene Glycol Isopropanolamine Ammonium Sulfate Carboxymethylcellulose Disodium Phosphate Isopropyl Acetate Antifoams Caustic Potash D'Limonene Isopropyl Alcohol Antifreeze Caustic Soda (All Grades) Dodecylbenzene Sulfonic Acid Isopropyl Myristate Antimicrobials Caustic Soda (Beads, Prills) (DDBSA) Isopropyl Palmitate Antimony Oxide Cetyl Alcohol Dowfrost Itaconic Acid Aqua Ammonia Cetyl Palmitate Dowfrost HD Jojoba Oil Ascorbic Acid Chlorine, Granular Dowtherm SR-1 Keratin Barium Carbonate Chloroform Dowtherm 4000 Lactic Acid Barium Chloride Chromic Acid EDTA Lanolin Beeswax Citric Acid (Dry and Liquid) EDTA Plus Lauric Acid Bentonite Coal Epsom Salt Lauryl Alcohol Benzaldehyde Cocamide DEA Ethyl Acetate Lecithin Benzoic Acid Copper Nitrate Ethyl Alcohol (Denatured) Lime Benzyl Alcohol Copper Sulfate Ethylene Glycol Linoleic Acid Bicarbonate
    [Show full text]
  • Potassium-Magnesium Citrate Is an Effective Prophylaxis Against Recurrent Calcium Oxalate Nephrolithiasis
    0022-5347/97/1586-2069$03.00/0 JOURNAL OF UROLOGY Vol. 158,2069-2073, December 1997 Copyright Q 1997 by AMERICANUROLOGICAL ASS~CIATION, INC. Printed in U.S.A. POTASSIUM-MAGNESIUM CITRATE IS AN EFFECTIVE PROPHYLAXIS AGAINST RECURRENT CALCIUM OXALATE NEPHROLITHIASIS BRUCE ETTINGER,* CHARLES Y. C. PAK, JOHN T. CITRON, CARL THOMAS, BEVERLEY ADAMS-HIJET AND ARLINE VANGESSEL From the Diuision of Research, Kaiser Permanente Medical Care Program, Oakland, California, the Department of Mineral Metabolism, Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, Department of Medicine, Kaiser Permanente Medical Center, Walnut Creek, California, Department of Urology, Kaiser Permanente Medical Center, San Francisco, California, and Kaiser Foundation Research Institute, Kaiser Foundation Hospitals, Oakland, California ABSTRACT Purpose: We examined the efficacy of potassium-magnesium citrate in preventing recurrent calcium oxalate kidney calculi. Materials and Methods: We conducted a prospective double-blind study of 64 patients who were randomly assigned to receive placebo or potassium-magnesium citrate (42 mEq. potassium, 21 mEq. magnesium, and 63 mEq. citrate) daily for up to 3 years. Results. New calculi formed in 63.6%of subjects receiving placebo and in 12.9%of subjects receiving potassium-magnesiumcitrate. When compared with placebo, the relative risk of treat- ment failure for potassium-magnesium citrate was 0.16 (95%confidence interval 0.05 to 0.46). potassium-magnesium citrate had a statistically significant effect (relative risk 0.10,95%confi- dence interval 0.03 to 0.36) even after adjustment for possible confounders, including age, pretreatment calculous event rate and urinary biochemical abnormalities.
    [Show full text]
  • Laxatives for the Management of Constipation in People Receiving Palliative Care (Review)
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by UCL Discovery Laxatives for the management of constipation in people receiving palliative care (Review) Candy B, Jones L, Larkin PJ, Vickerstaff V, Tookman A, Stone P This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2015, Issue 5 http://www.thecochranelibrary.com Laxatives for the management of constipation in people receiving palliative care (Review) Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 4 METHODS ...................................... 4 RESULTS....................................... 7 Figure1. ..................................... 8 Figure2. ..................................... 9 Figure3. ..................................... 10 DISCUSSION ..................................... 13 AUTHORS’CONCLUSIONS . 14 ACKNOWLEDGEMENTS . 14 REFERENCES ..................................... 15 CHARACTERISTICSOFSTUDIES . 17 DATAANDANALYSES. 26 ADDITIONALTABLES. 26 APPENDICES ..................................... 28 WHAT’SNEW..................................... 35 HISTORY....................................... 35 CONTRIBUTIONSOFAUTHORS . 36 DECLARATIONSOFINTEREST . 36 SOURCESOFSUPPORT . 36 DIFFERENCES
    [Show full text]
  • Cycle Stability and Hydration Behavior of Magnesium Oxide and Its Dependence on the Precursor-Related Particle Morphology
    nanomaterials Article Cycle Stability and Hydration Behavior of Magnesium Oxide and Its Dependence on the Precursor-Related Particle Morphology Georg Gravogl 1,2, Christian Knoll 2,3 , Jan M. Welch 4, Werner Artner 5, Norbert Freiberger 6, Roland Nilica 6, Elisabeth Eitenberger 7, Gernot Friedbacher 7, Michael Harasek 3 , Andreas Werner 8, Klaudia Hradil 5, Herwig Peterlik 9, Peter Weinberger 2 , Danny Müller 2,* and Ronald Miletich 1 1 Department of Mineralogy and Crystallography, University of Vienna, Althanstraße 14, 1090 Vienna, Austria; [email protected] (G.G.); [email protected] (R.M.) 2 Institute of Applied Synthetic Chemistry, TU Wien, Getreidemarkt 9, 1060 Vienna, Austria; [email protected] (C.K.); [email protected] (P.W.) 3 Institute of Chemical, Environmental & Biological Engineering, TU Wien, Getreidemarkt 9, 1060 Vienna, Austria; [email protected] 4 Atominstitut, TU Wien, Stadionallee 2, 1020 Vienna, Austria; [email protected] 5 X-ray Center, TU Wien, Getreidemarkt 9, 1060 Vienna, Austria; [email protected] (W.A.); [email protected] (K.H.) 6 RHI-AG, Magnesitstraße 2, 8700 Leoben, Austria; [email protected] (N.F.); [email protected] (R.N.) 7 Institute of Chemical Technologies and Analytics, TU Wien, Getreidemarkt 9, 1060 Vienna, Austria; [email protected] (E.E); [email protected] (G.F.) 8 Institute for Energy Systems and Thermodynamics, TU Wien, Getreidemarkt 9, 1060 Vienna, Austria; [email protected] 9 Faculty of Physics, University of Vienna, Boltzmanngasse 5, 1090 Vienna, Austria; [email protected] * Correspondence: [email protected]; Tel.: +43-1-5880-1163-740 Received: 31 August 2018; Accepted: 2 October 2018; Published: 7 October 2018 Abstract: Thermochemical energy storage is considered as an auspicious method for the recycling of medium-temperature waste heat.
    [Show full text]
  • Impact of a Drugs & Therapeutics Backgrounder on Docusate Utilization
    Impact of a Drugs & Therapeutics Backgrounder on Docusate Utilization Darren Pasay, B.Sc.Pharm Drug Stewardship Pharmacist (Central Zone) [email protected] Disclosure I have no actual or potential conflict of interest in relation to this topic or presentation. Drug Stewardship in Alberta Health Services • Drug Stewardship (DS) Team established in 2012 • “The shared responsibility of Drugs & Safety Therapeutics Committee (DTC), prescribers, pharmacy and care units to ensure Sustainability medications are used in a manner that maximizes the effectiveness, safety and sustainability of care for our patients” Effectiveness • Research and project support Drugs & Therapeutics Backgrounders (DTBs) • Frontline staff wanted background and support on DTC/formulary issues1 • One page document, meant to enhance conversations with prescribers • Supported by content experts, based upon DTC directions • Published 6 times/year • Followed by 2 interactive webinars for each edition 1. Pasay Darren K, Chow Sheldon JS, Bresee Lauren C, Guirguis Micheal, Slobodan Jeremy. Assessment of current antimicrobial stewardship policies and resources: a focus group project. Healthcare Infection 2015; 20: 7–15. Docusate • Over-the-counter stool softener • It is clear, based on published peer-reviewed literature, that docusate is ineffective for the prevention or treatment of constipation • Open listed on AHS Provincial Drug Formulary • Limited coverage on Alberta Drug Benefit List (palliative care only) Docusate DTB • Preliminary work o ~ 2 million doses/year dispensed • Influences o Some LTC sites have eliminated o Engrained in practice use already • Part of pharmacy, medicine, nursing curriculums • Order sets, Pre-printed care • What are the costs of? orders (PPCO) o Procurement o Seen as innocuous, safe o Processing, dispensing o Medication administration o Medication burden BOTTOM LINE: Docusate is no more effective than placebo for the prevention and treatment of constipation.
    [Show full text]
  • United States Patent Office Patented Nov
    3,539,306 United States Patent Office Patented Nov. 10, 1970 2 properties of quick activity, durable effect and storage 3,539,306 PROCESS FOR THE PREPARATION Stability, and that, therefore, the same can provide an ex OF HYDROTALCITE cellent, ideal antacid. Teruhiko Kumura and Norio Imataki, Takamatsu-shi, Hydrotalcite is known as a mineral having a chemical Katuyuki Hasui, Kagawa-ken, and Takeo Inoue and 5 Structure of the formula Kimiaki Yasutomi, Nagao-machi, Kagawa-ken, Japan, assignors to Kyowa Chemical Industry Co., Ltd., Tokyo, MgAl(OH) 16CO3 4HO O Al2O3 6MgO CO2: 12H2O Japan, a corporation of Japan No Drawing. Filed July 21, 1967, Ser. No. 654,977 which has been naturally produced in only very limited Claims priority, application Japan, July 25, 1966, areas as Norway and Ural. Also a process for the syn 41/48,349; July 17, 1967, 42/45,658 O thesis of hydrotalcite was disclosed, which comprises add Int. C. COf 5/00, 7/00, A61k 27/06 ing Dry Ice or ammonium carbonate to a mixture of U.S. C. 23-315 4 Claims magnesium oxide and y-alumina or the thermal decom position product from of magnesium nitrate and aluminum nitrate, and thereafter maintaining the system at tempera ABSTRACT OF THE DISCLOSURE, tures below 325 C. and under elevated pressures of total A process for the preparation of hydrotalcite which 2,000-20,000 p.s.i. (Roy et al.: American Journal of comprises mixing an alumium component such as alumi Science 251, 350-353 (1953)). However this process is num Salt With a magnesium component such as magnesium obviously unpractical for industrial scale production of Salt in an aqueous medium in the presence of carbonate hydrotalcite, because the reaction system must be main ion at a pH of at least 8 and thereafter recovering the 20 tained under considerably high pressures.
    [Show full text]
  • Barcroft™ Magnesium Hydroxide Powders
    TECHNICAL BULLETIN Barcroft™ Magnesium Hydroxide Powders SPI Pharma’s line of magnesium hydroxide powders is available worldwide and These spray dried powders provides the consistent quality required for pharmaceutical use. These powders are specifically designed for are used in wet granulation and direct compression tableting and suspension use in antacid tablets. applications. The products listed are typical of the SPI Pharma magnesium Resuspendible powders are hydroxide powder product line. Products are customized upon request. used for Milk of Magnesia Typical products and properties: (MOM) and antacid suspensions. They are also used in the production of ™ Barcroft Assay Surface Area Comments Product (as Al(OH)3) salts of weak acids, such as magnesium citrate. 5100CG 95-100% 50 m2/g USP, EP, low lead (<125ppb) 5200M 95-100% 65 m2/g USP, EP, resuspendible • meet USP/EP code 5300D 95-100% 45 m2/g USP dense powder (0.7 g/ml) • available in low and high surface area to meet formulation requirements 5100CG is primarily used in wet granulated antacid and laxative tablets. It is free flowing and blends very well with other ingredients. It is low lead (<125 ppb) • products produce very and can be used in antacids that must meet USA’s California Proposition 65. consistent re-hydrated 5200M is a medium-density product specifically designed for rehydration from pourable gels (MOM) the powdered form to produce a smooth, viscous, nonseparating suspension. This is required for milk of magnesia (MOM) laxative systems. Barcroft™ 5200M • spray dried to control is cost-effective for shipment anywhere in the world since it eliminates the cost particle size and density of shipping water.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • What Treatments Work Best for Constipation in Children?
    Evidence Based Answers CLINICAL INQUIRIES from the Family Physicians Inquiries Network Zia Rahman, MD, and What treatments work best Fereshteh Gerayli, MD Johnson City Family Medicine for constipation in children? Residency Program, Johnson City, Tenn Nakia Joye Carter, MS Evidence-based answer Quillen College of Medicine Library, East Tennessee State Osmotic laxatives produce the best this approach (strength of recommendation University, Johnson City results. Fiber and behavior modification [SOR]: B for fiber, 1 randomized controlled may have a role. Increased fiber and trial [RCT]; C for behavior modification, 1 behavior modification are the most often small trial). recommended first steps in managing For pharmacologic management, the chronic functional constipation (CFC) in best evidence supports osmotic laxatives children, but only limited evidence supports (SOR: A, 6 fair- to good-quality RCTs). z Evidence summary in 51 children with CFC, 2 to 11 years CFC with or without encopresis is a com- of age.2 The mean number of defecations mon pediatric problem that’s distressing per week was higher for children on to both the child and family. High-quality PEG + E (3.12 vs 1.45; P<.001); straining RCTs on managing CFC are lacking. Our or pain and stool consistency improved. FAST TRACK search located 7 relevant RCTs1-7 and 2 One good-quality RCT (100 children, Polyethylene relevant systematic reviews.8,9 The TABLE 6 months to 15 years old with CFC) com- summarizes the RCTs. pared PEG + E with lactulose.3 Both sig- glycol plus nificantly increased stool frequency and electrolytes works Fiber may help—and doesn’t hurt decreased encopresis.
    [Show full text]
  • Determination of the Solubility Product of Groupii Hydroxides
    DETERMINATION OF THE SOLUBILITY PRODUCT OF GROUPII HYDROXIDES INTRODUCTION SOLUBILTY EQUILIBRIA Many systems in chemistry appear to be static when in fact they are in (dynamic) equilibrium. When a system is in dynamic equilibrium the rate of the forward process is equal to the rate of the reverse process. One of these equilibrium systems is solubility equilibrium. When an ionic salt is placed in water if the salt is soluble then the salt will break apart (dissociate) into ions and the solution will contain hydrated positive ions and hydrated negative ions. An example is the formation of Na+ (aq) and Cl- (aq) when NaCl is dissolved in water. Consulting solubility tables tell us that most hydroxides are insoluble and therefore do not dissociate into ions when in solution. For example the net ionic equation for the reaction between MgCl2 and KOH is shown below. (Equation 1, Figure 1). 2+ - Mg (aq) + 2(OH ) (aq) Mg(OH)2 (Equation 1) Figure (1) However, even compounds considered insoluble will form a small amount of ions in solution. If a salt is “insoluble” what is really happening is that the equilibrium for the formation of hydrated ions from the reaction between the solid salt and water lies very far to the left (toward the solid). The formation of this small amount of ions and their recombination make up a system in dynamic equilibrium. The equilibrium constant for this process is called the solubility product, Ksp. The equilibrium reaction and equilibrium constant expression for Mg(OH)2 is shown below. (Note that the Mg(OH)2 does not appear in the equilibrium expression since it is a solid.
    [Show full text]
  • An Integrated Approach to Magnesium Hydroxide Use in Water and Wastewater Treatment
    An Integrated Approach to Magnesium Hydroxide Use In Water and Wastewater Treatment By Nathaniel Barnes Dissertation Submitted to the Faculty of the Graduate School of Vanderbilt University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in Environmental Engineering May 8, 2020 Nashville, Tennessee Approved: Alan Bowers, Ph.D. Shihong Lin, Ph.D. John Ayers, Ph.D. Bridget Rogers, Ph.D. Eugene LeBoeuf, Ph.D. Copyright © 2020 by Nathaniel Barnes All rights reserved ii To my mother and father, for their endless compassion, tireless support, and unwavering belief in me. To sing the entirety of their praises would quadruple the length of this dissertation, but it is fair to say that without them, this entire enterprise would have devolved into a Sisyphean nightmare long ago. iii ACKNOWLEDGMENTS First and foremost, I would like to thank Dr. Alan Bowers for everything he has done to help me grow as a student, as an engineer, and as a person. His extraordinary knowledge of environmental chemistry never ceases to amaze me, nor does the the unfathomable depth of his patience. He has taught me a multitude of important things over the years, including that every tap, filter, pipe, and pump in the world should have his phone number on it, just in case. I would also like to thank Premier Magnesia for its support of this research and the valuable insights its personnel provided into the industry. Special thanks belong to Matt Madolora for being an exceptionally friendly and valuable point of contact. Lastly, I would like to express my sincere gratitude to everyone else who supported me on this endeavor.
    [Show full text]
  • Laxatives Or Methylnaltrexone for the Management of Constipation in Palliative Care Patients (Review)
    Laxatives or methylnaltrexone for the management of constipation in palliative care patients (Review) Candy B, Jones L, Goodman ML, Drake R, Tookman A This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2011, Issue 1 http://www.thecochranelibrary.com Laxatives or methylnaltrexone for the management of constipation in palliative care patients (Review) Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 3 BACKGROUND .................................... 4 OBJECTIVES ..................................... 4 METHODS...................................... 5 RESULTS....................................... 7 Figure1. ..................................... 8 Figure2. ..................................... 9 DISCUSSION ..................................... 13 AUTHORS’CONCLUSIONS . 14 ACKNOWLEDGEMENTS . 15 REFERENCES..................................... 15 CHARACTERISTICSOFSTUDIES . .. 17 DATAANDANALYSES. 28 Analysis 1.1. Comparison 1 Methylnaltrexone versus placebo, Outcome 1 Proportion who had rescue-free laxation within 4hours..................................... 28 Analysis 1.2. Comparison 1 Methylnaltrexone versus placebo, Outcome 2 Laxation within 24 hours. 29 Analysis 1.3. Comparison 1 Methylnaltrexone versus placebo, Outcome 3 Tolerability: proportion
    [Show full text]